Palatin Technologies Inc. Daily Stock Analysis

Daily Stock Analysis, PTN, Palatin Technologies Inc, priceseries

Palatin Technologies Inc. Daily Stock Analysis
Stock Information
Open
0.39
Close
0.39
High
0.40
Low
0.39
Previous Close
0.40
Daily Price Gain
-0.01
YTD High
0.55
YTD High Date
Jan 3, 2022
YTD Low
0.36
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.15
YTD Gain
-27.76%
52 Week High
0.96
52 Week High Date
Nov 29, 2021
52 Week Low
0.33
52 Week Low Date
Nov 23, 2021
52 Week Price Change
-0.29
52 Week Gain
-42.63%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 12. 2018
0.95
Mar 27. 2018
1.04
11 Trading Days
8.66%
Link
LONG
Mar 29. 2018
1.09
Apr 18. 2018
1.32
13 Trading Days
21.25%
Link
LONG
May 10. 2018
1.22
May 15. 2018
1.29
3 Trading Days
5.74%
Link
LONG
Apr 25. 2019
1.12
May 17. 2019
1.35
16 Trading Days
20.23%
Link
LONG
Jun 21. 2019
1.34
Jun 24. 2019
1.56
1 Trading Days
16.42%
Link
Company Information
Stock Symbol
PTN
Exchange
NYSE MKT
Company URL
http://www.palatin.com
Company Phone
609-495-2200
CEO
Carl Spana
Headquarters
New Jersey
Business Address
4B CEDAR BROOK DRIVE, CRANBURY, NJ 08512
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0000911216
About

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic peptide receptor-specific programs, including PL-3994, a natriuretic peptide receptor-A, which is in Phase II clinical studies for treatment of heart failure, acute exacerbations of asthma, and refractory hypertension. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading